| All subjects | Group A | Group B | Group C | p-value | |
| Subjects n | 55 | 5 | 19 | ||
| Females | 40/77 (52) | 29 | 3 | 8 | >0.1 |
| Age at diagnosis with sarcoidosis yrs | 44 (41–47) | 42 (38–46) | 52 (43–62) | 49 (42–56) | >0.1 |
| Age at diagnosis with NHL yrs | 52 (48–56) | ||||
| Age at diagnosis with HL yrs | 45 (39–51) | ||||
| Interval between diseases months | 96 (69–123) | 36 (7–65) | <0.05 | ||
| NHL | 48/76 (63) | 32 | 5 | 11 | >0.1 |
| HL | 28/76 (37) | 20 | 0 | 8 | >0.1 |
| Stage 0 | 11/73 (15) | 8 | 1 | 2 | >0.1 |
| Stage I | 21/73 (29) | 14 | 2 | 5 | >0.1 |
| Stage II | 21/73 (29) | 16 | 0 | 5 | >0.1 |
| Stage III | 20/73 (27) | 14 | 2 | 4 | >0.1 |
| Organs involved in sarcoidosis | 3 (2.6–3.4) | 2.4 (1–3.8) | 2 (1.5–2.4) | <0.05 | |
| After second disease onset | |||||
| Cough | 3/40 | 4/16 | 0.09 | ||
| Dyspnoea | 4/40 | 6/16 | <0.05 | ||
| Elevated ACE | 0/40 | 4/16 | <0.05 | ||
| Lung | 0/40 | 9/16 | <0.05 | ||
| BHL | 2/40 | 8/16 | <0.05 | ||
| Skin | 3/40 | 4/16 | 0.09 | ||
| Lymph nodes | 20/40 | 0/16 | <0.05 | ||
| Spleen | 13/40 | 0/16 | <0.05 |
Data are presented as n/N (%), mean (95% CI) or n/N, unless otherwise stated. NHL: non-Hodgkin Lymphomal; HL: Hodgkin Lymphoma; ACE: angiotensin-converting enzyme; BHL: bilateral hilar lymphadenopathy.